Published Online
on June 9, 2003

A more recent version of this article appeared on June 17, 2003

This Article Full Text (PDF) All Versions of this Article: 107/23/2884    most recent 01.CIR.0000077530.53367.E9v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anand, S. S. Search for Related Content PubMed PubMed Citation Articles by Anand, S. S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID HEPARIN Medline Plus Health Information Blood Thinners Related Collections Anticoagulant mechanisms Arterial thrombosis Other anticoagulants Acute coronary syndromes

Submitted on December 17, 2002
Revised on March 25, 2003
Accepted on March 26, 2003

Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin

Sonia S. Anand MD, MSc, FRCP(c)^*, Salim Yusuf DPhil, FRCP, Janice Pogue MSc, Jeffrey S. Ginsberg MD, FRCP(c), Jack Hirsh MD, FRCP(c), and on Behalf of the Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators

From the Population Health Research Institute (S.S.A., S.Y., J.P.) and Henderson Research Centre (J.S.G., J.H.), McMaster University, Hamilton, Canada, and the Divisions of Cardiology and Thrombosis, Department of Medicine (S.S.A., S.Y., J.P., J.S.G., J.H.), McMaster University, Hamilton, Canada.

^* To whom correspondence should be addressed. E-mail: anands{at}mcmaster.ca.

Background--Antithrombotic therapy with intravenous heparin in conjunction with aspirin reduces negative cardiovascular (CV) outcomes in patients with acute coronary syndromes. The need for a therapeutic range with the activated partial thromboplastin time (APTT) has not been validated in patients with arterial thrombosis who receive heparin. Therefore, it is unclear whether there is an association between recurrent CV events and low APTT values and between bleeding and high APTT values.

Methods and Results--We examined the relationship between the APTT and recurrent cardiovascular events and bleeding among 5058 patients with an acute coronary syndrome without ST elevation who received intravenous heparin in the OASIS-2 trial. The increase in relative risk of recurrent CV events was 1.54 (95% CI 1.10 to 2.15; P=0.01) among patients with APTT values <60 seconds compared with patients with APTT values 60 seconds. When patients had persistently subtherapeutic APTT values for more than 48 hours, the increase in relative risk of a recurrent CV event was 1.84 (95% CI 1.25 to 2.70). Higher APTT values were associated with bleeding; for every 10-second increase in the APTT, the probability of major bleeding was increased by 7% (95% CI 3% to 11%; P=0.0004).

Conclusions--In patients with acute coronary syndromes without ST elevation who are treated with intravenous heparin, our findings justify regular APTT monitoring to minimize recurrent ischemic events and bleeding.

Key words: heparin • thrombosis • coronary disease

This article has been cited by other articles:

				S. R. Bauer, N. N. Ou, B. J. Dreesman, J. J. Armon, J. A. Anderson, S. S. Cha, and L. J. Oyen Effect of Body Mass Index on Bleeding Frequency and Activated Partial Thromboplastin Time in Weight-Based Dosing of Unfractionated Heparin: A Retrospective Cohort Study Mayo Clin. Proc., December 1, 2009; 84(12): 1073 - 1078. [Abstract] [Full Text] [PDF]

				S. Cheng, D. A. Morrow, S. Sloan, E. M. Antman, and M. S. Sabatine Predictors of Initial Nontherapeutic Anticoagulation With Unfractionated Heparin in ST-Segment Elevation Myocardial Infarction Circulation, March 10, 2009; 119(9): 1195 - 1202. [Abstract] [Full Text] [PDF]

				J. W. Eikelboom and J. I. Weitz Anticoagulation for ST-Segment Elevation Myocardial Infarction Circulation, March 10, 2009; 119(9): 1186 - 1188. [Full Text] [PDF]

				J. C. Roussel, T. Senage, O. Baron, C. Perigaud, O. Habash, J. C. Rigal, M. Treilhaud, J. N. Trochu, P. Despins, and D. Duveau CardioWest (Jarvik) Total Artificial Heart: A Single-Center Experience With 42 Patients Ann. Thorac. Surg., January 1, 2009; 87(1): 124 - 130. [Abstract] [Full Text] [PDF]

				S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 257S - 298S. [Abstract] [Full Text] [PDF]

				J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 299S - 339S. [Abstract] [Full Text] [PDF]

				R. Schreiber Low-molecular-weight heparin vs unfractionated heparin in acute coronary syndromes. JAMA, May 24, 2006; 295(20): 2353 - 2353. [Full Text] [PDF]

				K. W. Mahaffey and S. G. Goodman Low-Molecular-Weight Heparin vs Unfractionated Heparin in Acute Coronary Syndromes--Reply JAMA, May 24, 2006; 295(20): 2353 - 2354. [Full Text] [PDF]

				B. K. Nallamothu, E. R. Bates, J. S. Hochman, C. B. Granger, V. Guetta, R. G. Wilcox, H. D. White, P. W. Armstrong, S. Savonitto, G. Jia, et al. Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial Eur. Heart J., August 1, 2005; 26(15): 1506 - 1512. [Abstract] [Full Text] [PDF]

				P. G. Steg and J.-M. Juliard Enoxaparin in non-ST segment elevation acute coronary syndromes: duration of therapy is essential to benefit Eur. Heart J., October 1, 2004; 25(19): 1667 - 1669. [Full Text] [PDF]

				M. N. Levine, G. Raskob, R. J. Beyth, C. Kearon, and S. Schulman Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 287S - 310S. [Abstract] [Full Text] [PDF]

				G. Montalescot, J.P. Collet, M.L. Tanguy, A. Ankri, L. Payot, R. Dumaine, R. Choussat, F. Beygui, V. Gallois, and D. Thomas Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin Circulation, July 27, 2004; 110(4): 392 - 398. [Abstract] [Full Text] [PDF]